Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs)

F. Bonella (Essen, Germany), T. Maher (London, United Kingdom), V. Cottin (Lyon, France), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), F. Voss (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany)

Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Bonella (Essen, Germany), T. Maher (London, United Kingdom), V. Cottin (Lyon, France), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), F. Voss (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany). Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs). 739

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: